MX2018012039A - Inhibidores macrociclicos de interacciones proteina/proteina de proteina de muerte programada 1/ligando de muerte programada 1 (pd-1/pd-l1) y cumulo de diferenciacion 80/ ligando de muerte programada 1 (cd80/pd-l1). - Google Patents
Inhibidores macrociclicos de interacciones proteina/proteina de proteina de muerte programada 1/ligando de muerte programada 1 (pd-1/pd-l1) y cumulo de diferenciacion 80/ ligando de muerte programada 1 (cd80/pd-l1).Info
- Publication number
- MX2018012039A MX2018012039A MX2018012039A MX2018012039A MX2018012039A MX 2018012039 A MX2018012039 A MX 2018012039A MX 2018012039 A MX2018012039 A MX 2018012039A MX 2018012039 A MX2018012039 A MX 2018012039A MX 2018012039 A MX2018012039 A MX 2018012039A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- interactions
- macrocyclic inhibitors
- macrocyclic
- inhibitors
- Prior art date
Links
- 102000008096 B7-H1 Antigen Human genes 0.000 title abstract 2
- 108010074708 B7-H1 Antigen Proteins 0.000 title abstract 2
- 230000006916 protein interaction Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662318417P | 2016-04-05 | 2016-04-05 | |
| US15/475,227 US10358463B2 (en) | 2016-04-05 | 2017-03-31 | Immunomodulators |
| PCT/US2017/025677 WO2017176608A1 (en) | 2016-04-05 | 2017-04-03 | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018012039A true MX2018012039A (es) | 2019-01-14 |
Family
ID=59960204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012039A MX2018012039A (es) | 2016-04-05 | 2017-04-03 | Inhibidores macrociclicos de interacciones proteina/proteina de proteina de muerte programada 1/ligando de muerte programada 1 (pd-1/pd-l1) y cumulo de diferenciacion 80/ ligando de muerte programada 1 (cd80/pd-l1). |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10358463B2 (OSRAM) |
| EP (1) | EP3440097B1 (OSRAM) |
| JP (1) | JP7122255B2 (OSRAM) |
| KR (1) | KR102548798B1 (OSRAM) |
| CN (1) | CN109311943A (OSRAM) |
| AR (1) | AR108186A1 (OSRAM) |
| AU (1) | AU2017246216A1 (OSRAM) |
| BR (1) | BR112018070377A2 (OSRAM) |
| CA (1) | CA3020300A1 (OSRAM) |
| EA (1) | EA201892243A1 (OSRAM) |
| ES (1) | ES2998042T3 (OSRAM) |
| IL (1) | IL262126A (OSRAM) |
| MA (1) | MA43774A (OSRAM) |
| MX (1) | MX2018012039A (OSRAM) |
| SG (1) | SG11201808678QA (OSRAM) |
| TW (1) | TW201738260A (OSRAM) |
| UY (1) | UY37194A (OSRAM) |
| WO (1) | WO2017176608A1 (OSRAM) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| US9861680B2 (en) * | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
| US9944678B2 (en) * | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
| EA038019B1 (ru) | 2016-05-19 | 2021-06-23 | Бристол-Маерс Сквибб Компани | Иммуномодуляторы для пэт-визуализации |
| BR112019007450A2 (pt) | 2016-10-14 | 2020-07-07 | Precision Biosciences, Inc. | meganucleases modificadas específicas para sequências de reconhecimento no genoma do vírus da hepatite b |
| WO2018085750A2 (en) | 2016-11-07 | 2018-05-11 | Bristol-Myers Squibb Company | Immunomodulators |
| AU2017384900B2 (en) | 2016-12-28 | 2020-12-10 | GC Cell Corporation | Chimeric antigen receptor and natural killer cells expressing same |
| EP3642220A1 (en) * | 2017-06-23 | 2020-04-29 | Bristol-Myers Squibb Company | Immunomodulators acting as antagonists of pd-1 |
| EP3692053A1 (en) | 2017-10-03 | 2020-08-12 | Bristol-Myers Squibb Company | Immunomodulators |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CN111655732B (zh) | 2017-11-14 | 2023-09-12 | Gc细胞治疗 | 抗her2抗体或其抗原结合片段及包含其的嵌合抗原受体 |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| EP3728282B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| EP3746077A4 (en) * | 2018-02-02 | 2021-10-27 | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) | PARENTERAL FORMULATIONS AND THEIR USES |
| CN111712494A (zh) | 2018-02-13 | 2020-09-25 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| EP4600247A3 (en) | 2018-04-19 | 2025-11-19 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| CN118130807A (zh) | 2018-05-31 | 2024-06-04 | 小野药品工业株式会社 | 用于确定免疫检查点抑制剂的有效性的生物标志物 |
| EP3810109B1 (en) | 2018-05-31 | 2024-08-07 | Peloton Therapeutics, Inc. | Compounds and compositions for inhibiting cd73 |
| KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| TWI855000B (zh) | 2018-10-11 | 2024-09-11 | 日商小野藥品工業股份有限公司 | Ｓｔｉｎｇ促效化合物 |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| CN113227089B (zh) | 2018-10-31 | 2024-07-05 | 吉利德科学公司 | 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物 |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| JP2022526960A (ja) | 2019-03-28 | 2022-05-27 | ブリストル－マイヤーズ スクイブ カンパニー | 腫瘍を処置する方法 |
| EP3946625A1 (en) | 2019-03-28 | 2022-02-09 | Bristol-Myers Squibb Company | Methods of treating tumor |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| KR20220010535A (ko) * | 2019-05-21 | 2022-01-25 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| EP3977132A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
| CN114174538A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 适合于免疫肿瘤学疗法的多肿瘤基因特征 |
| WO2021025031A1 (ja) | 2019-08-05 | 2021-02-11 | 小野薬品工業株式会社 | 免疫チェックポイント阻害薬の有効性判定バイオマーカー |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| BR112022004316A2 (pt) | 2019-09-22 | 2022-06-21 | Bristol Myers Squibb Co | Caracterização espacial quantitativa para terapia de antagonista lag-3 |
| HRP20241379T1 (hr) | 2019-09-30 | 2024-12-20 | Gilead Sciences, Inc. | Cjepiva za hbv i postupci za liječenje hbv |
| KR20220093349A (ko) | 2019-11-08 | 2022-07-05 | 브리스톨-마이어스 스큅 컴퍼니 | 흑색종에 대한 lag-3 길항제 요법 |
| ES2970395T3 (es) * | 2019-11-19 | 2024-05-28 | Bristol Myers Squibb Co | Péptidos macrocíclicos como inhibidores de PD-L1 e inmunomoduladores para el tratamiento de cáncer y enfermedades infecciosas |
| ES3022990T3 (en) | 2019-12-06 | 2025-05-29 | Prec Biosciences Inc | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| WO2021141682A1 (en) * | 2020-01-06 | 2021-07-15 | Bristol-Myers Squibb Company | Macrocyclic peptides as pd-l1 inhibitors and immunomodulators for the treatment of cancer and infectious diseases |
| EP4087857B1 (en) * | 2020-01-06 | 2023-11-01 | Bristol-Myers Squibb Company | Immunomodulators |
| TWI845826B (zh) | 2020-03-20 | 2024-06-21 | 美商基利科學股份有限公司 | 4'-c-經取代-2-鹵基-2'-去氧腺苷核苷之前藥及其製造與使用方法 |
| KR20220161407A (ko) * | 2020-03-30 | 2022-12-06 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제 |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| JPWO2021205631A1 (OSRAM) | 2020-04-10 | 2021-10-14 | ||
| CN113754736A (zh) * | 2020-06-02 | 2021-12-07 | 南京礼威生物医药有限公司 | 含酰肼结构的pd-l1环肽抑制剂 |
| CN111961117B (zh) * | 2020-08-19 | 2022-03-11 | 中山大学 | 一种环肽化合物及其应用 |
| MX2023002332A (es) | 2020-08-28 | 2023-03-21 | Bristol Myers Squibb Co | Terapia con antagonistas del gen 3 de activacion de linfocitos (lag-3) para carcinoma hepatocelular. |
| CA3190660A1 (en) | 2020-08-31 | 2022-03-03 | George C. Lee | Cell localization signature and immunotherapy |
| CA3196496A1 (en) | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| JP2024514245A (ja) | 2021-03-29 | 2024-03-29 | ジュノー セラピューティクス インコーポレイテッド | チェックポイント阻害剤療法とｃａｒ ｔ細胞療法との組合せを用いた投薬および処置のための方法 |
| TW202348237A (zh) | 2021-05-13 | 2023-12-16 | 美商基利科學股份有限公司 | TLR8調節化合物及抗HBV siRNA療法之組合 |
| KR20240019236A (ko) * | 2021-06-09 | 2024-02-14 | 브리스톨-마이어스 스큅 컴퍼니 | 시클릭 펩티드 면역조정제 |
| AU2022291381B2 (en) | 2021-06-11 | 2025-04-24 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| EP4351657A1 (en) | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN118176214A (zh) | 2021-10-29 | 2024-06-11 | 百时美施贵宝公司 | 血液癌症的lag-3拮抗剂疗法 |
| MX2024008831A (es) | 2022-01-26 | 2024-07-25 | Bristol Myers Squibb Co | Terapia combinada para carcinoma hepatocelular. |
| CN119731651A (zh) | 2022-04-08 | 2025-03-28 | 百时美施贵宝公司 | 三级淋巴结构的机器学习标识、分类和量化 |
| IL318949A (en) | 2022-08-23 | 2025-04-01 | Ono Pharmaceutical Co | Bispecific antibody |
| WO2024137776A1 (en) | 2022-12-21 | 2024-06-27 | Bristol-Myers Squibb Company | Combination therapy for lung cancer |
| WO2024163691A1 (en) | 2023-02-03 | 2024-08-08 | Merck Sharp & Dohme Llc | Cyclic peptides for inhibiting tnf receptor 1 activity |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2025061971A1 (en) | 2023-09-20 | 2025-03-27 | Trimt Gmbh | Functionalized peptides for in-vivo addressing of pd-l1 expression |
| WO2025166198A1 (en) * | 2024-02-01 | 2025-08-07 | Merck Sharp & Dohme Llc | Methods of using cyclic peptides that bind to tnfr1 |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US6277818B1 (en) | 1998-10-29 | 2001-08-21 | Angstrom Pharmaceuticals, Inc. | Cyclic peptide ligands that target urokinase plasminogen activator receptor |
| EP1240182A2 (en) * | 1999-12-15 | 2002-09-18 | Cubist Pharmaceuticals, Inc. | Daptomycin analogs and their use as antibacterial agents |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP2141175B1 (en) | 2007-03-26 | 2016-07-27 | The University of Tokyo | Process for synthesizing cyclic peptide compound |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| JP5818237B2 (ja) | 2010-09-09 | 2015-11-18 | 国立大学法人 東京大学 | Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法 |
| EP2647720B1 (en) | 2010-12-03 | 2019-06-19 | The University of Tokyo | Peptide library production method, peptide library, and screening method |
| WO2012168944A1 (en) | 2011-06-08 | 2012-12-13 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
| RU2014143443A (ru) | 2012-03-29 | 2016-05-20 | Ориджин Дискавери Текнолоджиз Лимитед | Иммуномодулирующие циклические соединения |
| JP2013253842A (ja) | 2012-06-06 | 2013-12-19 | Univ Of Tokyo | ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法 |
| ES2647076T3 (es) | 2012-06-06 | 2017-12-19 | Polyphor Ag | Peptidomiméticos de horquilla beta |
| KR20220053691A (ko) | 2013-03-15 | 2022-04-29 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| KR20160075506A (ko) | 2013-09-06 | 2016-06-29 | 오리진 디스커버리 테크놀로지스 리미티드 | 면역조절제로서 사이클릭 펩티도미메틱 화합물 |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| WO2015131100A1 (en) * | 2014-02-28 | 2015-09-03 | The Scripps Research Institute | Ligand-controlled c(sp3)-h arylation and olefination in synthesis of unnatural chiral alpha amino acids |
| EP3191113B1 (en) | 2014-09-11 | 2019-11-06 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-l1 protein/protein interactions |
| US9732119B2 (en) * | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| US9861680B2 (en) * | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
| US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
| EA038019B1 (ru) | 2016-05-19 | 2021-06-23 | Бристол-Маерс Сквибб Компани | Иммуномодуляторы для пэт-визуализации |
-
2017
- 2017-03-31 US US15/475,227 patent/US10358463B2/en active Active
- 2017-04-03 KR KR1020187031601A patent/KR102548798B1/ko active Active
- 2017-04-03 MX MX2018012039A patent/MX2018012039A/es unknown
- 2017-04-03 SG SG11201808678QA patent/SG11201808678QA/en unknown
- 2017-04-03 JP JP2018552242A patent/JP7122255B2/ja active Active
- 2017-04-03 CA CA3020300A patent/CA3020300A1/en not_active Abandoned
- 2017-04-03 AU AU2017246216A patent/AU2017246216A1/en not_active Abandoned
- 2017-04-03 WO PCT/US2017/025677 patent/WO2017176608A1/en not_active Ceased
- 2017-04-03 MA MA043774A patent/MA43774A/fr unknown
- 2017-04-03 EA EA201892243A patent/EA201892243A1/ru unknown
- 2017-04-03 CN CN201780033784.XA patent/CN109311943A/zh active Pending
- 2017-04-03 BR BR112018070377A patent/BR112018070377A2/pt not_active Application Discontinuation
- 2017-04-03 ES ES17718218T patent/ES2998042T3/es active Active
- 2017-04-03 EP EP17718218.5A patent/EP3440097B1/en active Active
- 2017-04-05 UY UY0001037194A patent/UY37194A/es unknown
- 2017-04-05 TW TW106111442A patent/TW201738260A/zh unknown
- 2017-04-05 AR ARP170100881A patent/AR108186A1/es unknown
-
2018
- 2018-10-04 IL IL262126A patent/IL262126A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019513734A (ja) | 2019-05-30 |
| MA43774A (fr) | 2018-11-28 |
| IL262126A (en) | 2018-11-29 |
| EP3440097B1 (en) | 2024-10-23 |
| TW201738260A (zh) | 2017-11-01 |
| KR20180132775A (ko) | 2018-12-12 |
| CA3020300A1 (en) | 2017-10-12 |
| JP7122255B2 (ja) | 2022-08-19 |
| UY37194A (es) | 2017-10-31 |
| EP3440097A1 (en) | 2019-02-13 |
| AU2017246216A1 (en) | 2018-11-22 |
| KR102548798B1 (ko) | 2023-06-27 |
| SG11201808678QA (en) | 2018-11-29 |
| BR112018070377A2 (pt) | 2019-02-05 |
| US10358463B2 (en) | 2019-07-23 |
| WO2017176608A1 (en) | 2017-10-12 |
| US20170283463A1 (en) | 2017-10-05 |
| CN109311943A (zh) | 2019-02-05 |
| EA201892243A1 (ru) | 2019-03-29 |
| AR108186A1 (es) | 2018-07-25 |
| ES2998042T3 (en) | 2025-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018012039A (es) | Inhibidores macrociclicos de interacciones proteina/proteina de proteina de muerte programada 1/ligando de muerte programada 1 (pd-1/pd-l1) y cumulo de diferenciacion 80/ ligando de muerte programada 1 (cd80/pd-l1). | |
| PH12017500441A1 (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions | |
| MX2017008160A (es) | Inmunomoduladores. | |
| MX2017011960A (es) | Inmunomoduladores. | |
| MX2017010129A (es) | Inmunomoduladores. | |
| MX2017007677A (es) | Inmunomoduladores. | |
| MX2017004542A (es) | Inmunomoduladores. | |
| TN2015000418A1 (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions | |
| MX379487B (es) | Inmunomoduladores. | |
| MX2016013028A (es) | Compuestos utiles como inmunomoduladores. | |
| PH12017500858A1 (en) | Mocrocyclic peptides useful as immunomodulators | |
| MX2017001981A (es) | Inhibidores de diana de rapamicina en celulas de mamifero de complejo 1 (mtorc1). | |
| UY35733A (es) | Inhibidores macrocíclicos de las interacciones proteína/proteína pd-1/pd-l1 y cd80(b7-1)/pd-l1 i.p.c. | |
| TH169591A (th) | สารยับยั้งชนิดมาโครไซคลิกของการทำอันตรกิริยาของโปรตีน/โปรตีนของ pd-1/pd-l1 และ cd80(b7-1)/pd-l1 |